Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 1078 clinical trials
NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors

NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in n=6 patients with solid tumors

  • 25 May, 2022
Hypopharynx ICG to Reduce the Fistula Rate in Patients Undergoing Salvage Laryngectomy

A laryngectomy involves removing the voice box from the throat. After the voice box has been removed from the throat, the surgeon sews the throat closed. Sometimes part of the throat does not heal and saliva runs out of the throat. This is called a fistula. When a fistula happens, …

  • 14 Jun, 2022
  • 1 location
Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer

The purpose of this study is to establish the efficacy and toxicity of low dose chemoradiotherapy after induction chemotherapy in patients with locally advanced HPV+ oropharynx cancer and establish prognostic factors that would apply to help select patients for this treatment in the future.

  • 23 Feb, 2022
  • 1 location
Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers (HART-HN)

The primary purpose of this study is to determine the safe reduction of the treatment fractions to 10, 8, or 5, that may be delivered safely in resected head and neck squamous cell carcinoma (HNSCC) patients with intermediate pathologic risk features.

  • 21 Mar, 2022
  • 1 location
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

primary tumor
carcinoma of oropharynx
squamous cell carcinoma
measurable disease
  • 30 May, 2022
  • 40 locations
DAHANCA 35: Proton Versus Photon Therapy for Head-neck Cancer

Patients with squamous cell carcinoma of the pharynx or larynx and an anticipated benefit of proton radiotherapy in reducing the risk of late dysphagia or xerostomia are randomized to proton or photon radiotherapy (2:1)

squamous cell carcinoma
  • 25 Jan, 2021
  • 7 locations
PRO-ACTIVE: Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer (PRO-ACTIVE)

Dysphagia (difficulty swallowing) is a common and potentially life-threatening toxicity of radiotherapy (RT) for patients with head and neck cancer (HNC). HNC survivors have a 20-24 percent

swallowing therapy
impaired swallowing
  • 23 Mar, 2022
  • 12 locations
  • 06 Jun, 2022
  • 122 locations
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

This study is open to adults with head and neck cancer or liver cancer. This is a study for people for whom previous treatment was not successful or no standard treatment exists. The purpose of

  • 19 Jun, 2022
  • 10 locations
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy …

ct scan
carcinoma of oropharynx
squamous cell carcinoma
intensity-modulated radiation therapy
  • 13 Jun, 2022
  • 131 locations